Bioniche Life Sciences Inc. Securities Now Trading on the Australian Securities Exchange (ASX)

-effective January 27, 2011 at 11:00 a.m. AEST-

BELLEVILLE, ON, Jan. 27 /CNW/ - Bioniche Life Sciences Inc. (TSX&ASX: BNC), a research-based, technology-driven Canadian biopharmaceutical company, today announced that it has joined the official list of the Australian Securities Exchange (ASX) and its securities are now trading on that exchange under the code "BNC".

The ASX listing follows the Company's completion of an Australian Offer of 8.6 million CHESS Depositary Instruments (CDIs) at A$1.45 per CDI. Combined with an additional C$16.7 million raised through a concurrent Canadian Offer of 11.5 million Common Shares at C$1.45 per Share that closed on December 16, 2010, the Company raised a total of C$28.9 million in gross proceeds (based on actual exchange rates).

The holders of CDIs in Australia hold the beneficial ownership of the equivalent number of Common Shares in the Company, while the legal title in those Shares is held by a depositary nominee (in this case, CHESS Depositary Nominees Pty Ltd (CDN), a wholly owned subsidiary of the ASX). CDIs are held in uncertified form and enable investors to hold and transfer their interests in foreign financial products electronically through CHESS. CDIs must be converted into Shares in order to trade on the TSX. Conversely, TSX-issued Shares must be converted into CDIs in order to trade on the ASX.

About Bioniche Life Sciences Inc.

Bioniche Life Sciences Inc. is a research-based, technology-driven Canadian biopharmaceutical company focused on the discovery, development, manufacturing, and marketing of proprietary products for human and animal health markets worldwide. The fully-integrated company employs 217 skilled personnel and has three operating divisions: Human Health, Animal Health, and Food Safety. The Company's primary goal is to develop proprietary cancer therapies supported by revenues from marketed products in human and animal health. Bioniche Life Sciences Inc. has been named one of the Top 50 Best Small and Medium-Sized Employers in Canada for 2010. For more information, please visit

Except for historical information, this news release may contain forward-looking statements that reflect the Company's current expectation regarding future events. These forward-looking statements involve risk and uncertainties, which may cause, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting.

SOURCE Bioniche Life Sciences Inc.

For further information:

Jennifer Shea, Vice-President, Communications, Investor & Government Relations
Bioniche Life Sciences Inc.
Telephone: (613) 966-8058
Cell: (613) 391-2097

Profil de l'entreprise

Bioniche Life Sciences Inc.

Renseignements sur cet organisme


Jetez un coup d’œil sur nos forfaits personnalisés ou créez le vôtre selon vos besoins de communication particuliers.

Commencez dès aujourd'hui .


Remplissez un formulaire d'adhésion à CNW ou communiquez avec nous au 1-877-269-7890.


Demandez plus d'informations sur les produits et services de CNW ou communiquez avec nous au 1‑877-269-7890.